FindTrial
Sign In

Application of HPV E6/E7 mRNA test in cervical cancer screening: a multicenter study

Application of HPV E6/E7 mRNA test in cervical cancer screening: a multicenter study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070427
Enrollment
Unknown
Registered
2023-04-11
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV infection

Interventions

Gold Standard:Pathology results
Index test:HPV E6/E7 mRNA

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Gynecological patients with TCT and/or HPV abnormalities requiring colposcopy, aged 21-59 years; 2. Volunteer to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of pelvic chemoradiotherapy, cervical surgery or total hysterectomy; 2. Patients who are pregnant or within 8 weeks after delivery; 3. Patients with acute genital tract inflammation.

Design outcomes

Primary

MeasureTime frame
HPV E6/E7 mRNA;pathology results;accuracy;sensitivity;specificity;—

Secondary

MeasureTime frame
seq HPV;—

Countries

China

Contacts

Public ContactWu Ruifang

Peking University Shenzhen Hospital

wurf100@126.com+86 138 2743 3039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026